November 25, 2024
Short trading week, U.S. markets are closed Thursday due to the Thanksgiving holiday and close early on Friday, so trading volume is likely to be light this week
Also hoping to suffer from a compound called tryptophan; an amino acid creating serotonin in the body from eating turkey to play a role in my sleep regulation
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
MY Pre-Open Thoughts: “let ‘em run”
Never leave an investor uninform
November 17, 2024
A scorecard of earnings releases of covered companies
Reporting to date - 34
The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status".
November 25, 2024
Sector trades higher at the start of the shortened week awaiting Wednesday's Personal Consumption Expenditures (PCE) report
Although, trading volume is likely to be light this week due to the Thanksgiving holiday and close early on Friday
It’s about defining insight. Who speaks out while standing in-front, beside and behind investors – RMi
Never leave an investor uninformed!
November 17, 2024
A scorecard of earnings releases of covered companies Reporting to date - 34 The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status".
November 7, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 21 reported (SAGE),(MDXG)(BPMC),(ALNY),(QURE), (BEAM), (RARE), (VERV), (ADVM), (EDIT), (CRSP), )RARE), (IONS), (LENZ), (CRBU), (SLDB), (RGNX), (GBIO), (MRNA), (VCEL), (AXGN), (NTLA( More to report: Agenus (AGEN), Sage Therapeutics (SAGE), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Voyager Therapeutics (VYGR) 11/12 Tuesday
October 3, 2024
Called “Monetization Financing with DRI Healthcare Trust” as access to capital markets is shaky EDIT sold certain future license fees and other payments owed under its Cas9 license agreement with Vertex Pharmaceuticals (VRTX)to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. EDIT closed down -$0.02 with only a +$0.06 or +1.87% aftermarket indication
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
